Highlights Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
20.23 ^USD	-4.17%		-8.25%	-10.13%

05-10	Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-08	Cassava Sciences Raises More Than $125 Million From Warrant Distribution	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Cassava Sciences Raises More Than $125 Million From Warrant Distribution	05-08	MT
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	03-25	MT
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	03-25	CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia	02-07	CI
Cassava Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer?S Disease	11-06	CI
Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients	25/10/23	CI
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer?s Disease	02/10/23	CI
Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer?s Disease	18/09/23	CI
Cassava Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study	05/07/23	CI
Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging	27/06/23	CI
Cassava Sciences Completes Patient Dosing in A Randomized Controlled Trial of Simufilam in Alzheimer’S Disease	11/05/23	CI
Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	01/05/23	CI
Cassava Sciences Posts Wider Q4 Loss	28/02/23	MT
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	28/02/23	CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Highlights

Filters